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Abstract
Secondary iron overload in patients with β-thalassemia is caused by multiple 
blood transfusions and increased iron absorption. Most of them die from cardiac 
arrest and infections while others from oxidative tissue damage and organ dysfunc-
tion. Under high saturation of transferrin with iron, redox-active iron such as non-
transferrin-bound iron, labile plasma iron, and cellular labile iron pool is prone to 
the production of reactive oxygen species, oxidized biomolecules, oxidative tissue 
damages, and complications. Iron chelation therapy and antioxidant supplementa-
tion are a supportive treatment for patients’ better quality of life and life expec-
tancy. Green tea (Camellia sinensis) extract (GTE) is abundant with polyphenols, 
mainly epigallocatechin-3-gallate and nutraceuticals, which are beneficial for cell 
functions and health. Importantly, GTE possesses antioxidant, free radical scav-
enging, metal-chelating, anti-hemolysis properties in cell cultures, animals, and 
humans. This article has reported modes of actions and challenged such wonderful 
properties of green tea used to remove excessive iron, scavenge harmful radicals, 
restore malfunctions of vital organs, and treat patients with β-thalassemia with iron 
overload. Infeasibility and sustainability, the benefits of green tea can be applied for 
use in other diseases with iron toxicity and oxidative stress.
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1. Introduction
Erythrocytes or red blood cells (RBC) play a crucial role in oxygen carrying and 
transportation. The main component of RBC is hemoglobin (Hb) which consists of 
four subunits of globin chain with heme group at the center of each subunit. The types 
of Hb can be defined by different globin chain compositions. For instances, hemoglo-
bin A (HbA) consists of two α-globin chains and two β-globin chains (α2β2), which is 
found in high levels of normal human blood. Hemoglobin A2 (HbA2) consists of two 
α-globin chains and two δ-globin chains (α2δ2), which is found in low levels of normal 
human blood and may be increased in the blood of patients with β-thalassemia. Fetal 
hemoglobin (HbF) consists of two α-globin chains and two γ-globin chains (α2γ2), 
which is present in high levels in fetal and newborn human blood. Likewise, embry-
onic hemoglobin such as hemoglobin Gower I (ζ2ε2) and Gower II (α2ε2) are produced 
in early life and switched to other Hb types during development.
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Human β-thalassemia is characterized by mutations of β-globin gene, resulting 
in deficient production of the β-globin chains of Hb molecule (ineffective erythro-
poiesis) and chronic anemia. Over 200 mutations have been identified in this gene, 
and the type of mutations can influence the severity of the disease. Blood transfu-
sions aim to maintain normal Hb levels to prevent tissue hypoxia, whereas repeated 
blood transfusions lead to the inevitable consequence of iron accumulation in the 
body. Iron deposition occurs considerably in almost all tissues but is primarily 
located in the spleen, liver, heart, and endocrine glands. Besides ferritin iron and 
hemosiderin, the uncommon forms of iron including labile or transient iron pools 
(LIP) in the tissues, nonheme iron in RBC membrane, and non-transferrin-bound 
iron (NTBI) and labile iron pool (LPI) in plasma appear to be redox-active and 
subsequently generate reactive oxygen species (ROS) via Haber-Weiss and Fenton 
reactions. The ROS can oxidize biomolecules, causing oxidative tissue damage, 
organ dysfunctions, complications, and death. Effective iron chelation needs giving 
to counteract the resulting iron overload and prevent oxidative tissue damage. So 
far, monotherapy or combined therapy with iron chelators such as desferrioxamine 
(DFO), deferiprone (DFP), and deferasirox (DFX) has been used for the treat-
ment of patients with β-thalassemia with iron overload, but they present some side 
effects. Modified medical regimens such as adjunctive iron chelator and antioxidant 
and drug cocktail are purported to increase the chelation efficacy, minimize the side 
effects, and achieve additive chelation efficacy. Moreover, commercially available 
antioxidants such as vitamin C, vitamin E, and N-acetylcysteine (NAC) are usu-
ally given together with the chelators to relieve the oxidative stress in patients with 
thalassemia. Herein, an interesting natural product such as green tea extract from 
tea leaves (Camellia sinensis) has been documented in terms of bifunctional antioxi-
dant and iron-chelating properties in iron-overloaded cells and mouse and human 
thalassemia, rather than its general biological and pharmacological properties.
2. β-Thalassemia
2.1 Etiology and pathophysiology
β-Thalassemia is a quantitative hemoglobinopathy which impairs the produc-
tion of β-globin chains in Hb due to mutations of the gene located on the short arm 
of chromosome 11. Accordingly, a reduction of β+ or an absence of β0 in β-globin 
synthesis causes the precipitation of excessive unbound α-globin chains in ery-
throid precursors due to chain imbalances. The abnormal erythroid precursors 
are driven into apoptosis pathway during their differentiation and maturation in 
the bone marrow, consequently leading to erythroid expansion, accelerated extra-
medullary erythropoiesis, increased dietary iron absorption, and high turnover of 
RBC. Moreover, impaired β-globin synthesis and ineffective erythropoiesis result 
in microcytic anemia and progressive splenomegaly. There are three main types of 
β-thalassemia, in order of decreasing severity, homozygous β-thalassemia major 
(TM), β-thalassemia intermedia (TI), and heterozygous β-thalassemia minor. 
Hemoglobin E (HbE)/β-thalassemia is the most prevalent in Southeast Asia where 
the carrier frequency is around 50%. The interaction of HbE and β-thalassemia 
results in a clinical spectrum ranging from a severe condition that is indistinguish-
able from TM to a mild form of TI [1].
Nowadays, β-thalassemia is divided into transfusion-dependent β-thalassemia 
(TDT) and non-transfusion-dependent β-thalassemia (NTDT). In other mammals, 
mouse homozygous beta-globin knockout (BKO) thalassemia shows many clinical 
features of abnormal RBC indices including a decrease in blood Hb concentration, 
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hematocrit (Hct), RBC numbers, and osmotic fragility and an increase of reticulo-
cyte count. Likely, increased degradation of abnormal RBC is an important conse-
quence of unstable Hb and excessive membrane iron in patients with β-thalassemia. 
Invasive and noninvasive laboratory investigations reveal systemic and cellular iron 
overload in TDT and NTDT patients. Large amounts of the irons from enterocytes 
and reticuloendothelial (RE) macrophages in the spleen can get into plasma com-
partment and subsequently bind to transferrin (Tf). Accordingly, this can lead to 
a high saturation of Tf with iron, an appearance of NTBI and LPI, and high levels 
of ferritin in plasma compartment, together with high iron deposition ferritin (Ft) 
in several tissues in the body. Consequently, iron accumulation in the vital organs 
is the cause of susceptibility to infections and immunological abnormalities, liver 
diseases (e.g., hepatitis, hepatic fibrosis, and hepatocellular carcinoma), cardiomy-
opathies (e.g., cardiac arrhythmia and heart failure), and endocrine gland dysfunc-
tion (e.g., diabetes, growth retardation, hypogonadism, and hypoparathyroidism) 
[2–4]. Evidentially, most of patients with β-thalassemia with iron overload die of 
heart failure, while some patients frequently die from infections and suffer from 
liver diseases and endocrinopathies.
2.2 Iron overload and oxidative stress
2.2.1 Iron transport into cells
In fact, abnormal iron absorption in patients with thalassemia produces an 
increase in the body iron burden evaluated at 2–5 g per year, and regular blood 
transfusion (420 mL/U, equivalent to 200 mg of iron) leads to double iron accumu-
lation [5]. Normally, iron is bound to iron-transporting protein in plasma (called 
transferrin) and in milk (called lactoferrin), forms transferrin-bound iron (TBI), 
and is transported in blood circulation to target cells. The circulating TBI, which is 
low saturation in iron-deficiency persons, one-third saturation in normal people, 
and high saturation in iron overload patients, is taken up into iron-requiring 
target cells by using ATP-dependent transferrin receptor 1 (TfR1)-mediated 
endocytosis and delivered in cells for functions and storage in ferritin molecules 
(H- and L-subunits). When the capacity of transferrin to incorporate iron derived 
from gastrointestinal (GI) tract and RE cells becomes limited, the transferrin 
iron-binding capacity (TIBC) has been surpassed [6]. Afterward, two forms of 
redox-active iron such as NTBI and LPI appear primarily in plasma of patients with 
β-thalassemia. Pathologically, the NTBI fraction seems to translocate across plasma 
membrane via specific transporters on specific cell types. NTBI transporter which 
is originally called divalent metal ion transporter 1 (DMT1) or natural resistance-
associated macrophage protein 2 (Nramp2) is proposed to locate on intestinal epi-
thelial cells, erythroid cells and astrocytes, L-type calcium channel (LTCC), T-type 
calcium channel (TTCC) on cardiomyocytes, T-type calcium channel (TTCC) 
on hepatocytes, pancreatic islets β cells and kidney tubular cells, anion-exchange 
protein 2 (AE2) on bronchial epithelial cells, ferrireductases on kidney proximal 
tubule, and zinc ion protein 18 (ZIP18) on kidney tubular cells and hippocampal 
neuronal cells [7–14]. Importantly, NTBI and LPI are redox-active and susceptible 
to chelation [15].
2.2.2 Iron overload
The iron that cells do not require immediately for metabolic processes is stored 
in ferritin in the liver, enterocytes, and RE macrophages, representing the stor-
age iron pool. The iron that mobilizes transiently inside the cells is called LIP that 
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is potentially redox-active and increased when the cells are heavily loaded with 
a large number of extracellular irons, TBI, and NTBI. Iron distribution in the 
body is strictly regulated by two regulatory systems, systemic and cellular iron 
homeostasis. Systemic iron homeostasis strictly responds to ensure a balance of 
iron absorption and iron utilization, which relies on the hepatic hepcidin hormone 
and the ferroportin actions and occurs in enterocytes, hepatocytes, and splenic 
macrophages. Hepcidin levels found to decrease in primary hemochromatosis and 
secondary hemochromatosis such as TI patients due to an acceleration of eryth-
ropoietic activity driven by increases of erythropoietin (EPO) production and 
TfR1 expression. Inversely, hepcidin levels increased in TM patients due to blood 
transfusion that they do not need to increase erythropoiesis to compensate inef-
fective erythropoiesis [16]. The regulation will reduce iron efflux from ferroportin 
at the basolateral part of duodenal epithelial cells and from RE macrophage into 
the plasma, resulting in iron retention within the cells. Drugs or natural products 
that increase hepcidin expression and production would be beneficial for the 
supportive treatment of TI patients with iron overload. Cellular iron homeostasis 
is dependent on the expression and function of TfR1 and ferritin mediated by iron 
regulatory element (IRE)/iron regulatory protein (IRP) system. Once TBI is inter-
nalized into cells via TfR-mediated endocytosis, iron is mainly stored by ferritin 
inside the cells [17]. In patients with thalassemia, large amounts of iron from diet 
and degradation of effete RBC by RE macrophage drain into plasma transferrin 
and subsequently taken into cells. Consequently, this will result in iron overload, 
oxidative stress, and depletion of antioxidant defense systems in plasma compart-
ment and many vital organs in the body.
2.2.2.1 Blood
Thalassemia RBC containing large amounts of iron and low protective antioxi-
dant system is prone to be damaged by ROS, leading to chronic hemolytic anemia. 
In young patients with β-thalassemia, plasma and RBC levels of thiobarbituric 
acid-reactive substances (TBARS), superoxide dismutase (SOD), and ferritin 
were increased, but the level of catalase (CAT) was decreased when compared 
with normal children [18]. Interestingly, Aphinives and colleagues have found 
decreased levels of antioxidants such as reduced glutathione (GSH) and vascular 
endothelial dysfunction in young Thai patients with β-thalassemia with HbE 
patients [19]. Additionally, blood levels of CAT, glutathione-S-transferase (GST), 
GSH, and vitamin C were found to decrease in β-thalassemia major patients while 
blood SOD level was increased [20]. Importantly, the levels of blood antioxidant 
system including GST, glutathione peroxidase (GPx), glutathione reductase (GR), 
peroxiredoxin 2 (Prx2), thioredoxin 1, and thioredoxin reductase were decreased 
in β-thalassemia major patients with regular blood transfusion and iron chela-
tion therapy, whereas the blood levels of CAT and SOD were increased when 
compared to healthy subjects [21]. Consistently, the levels of red cell SOD, GPx, 
and CAT activities increased in hemoglobin H (HbH) disease (a moderately severe 
α-thalassemia) patients when compared to healthy control. However, the Chinese 
medicine “Yisui Shengxue” granules which have been officially prescribed and 
clinically used for the treatment of thalassemia for a long time effectively decreased 
the GPx and CAT activities but increased the SOD activity [22]. Prolonged bleeding 
times and abnormal platelet aggregation can be found in transfusion-dependent 
β-thalassemia major patients, possibly due to artifacts caused by in vitro manipula-
tions, oxidative platelets, and circulating procoagulants such as microparticles 
(MP) tissue factors and platelet-derived MP [23, 24]. Platelet numbers were 
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approximately 1.5- and 4-fold increase in Thai non-splenectomized and splenecto-
mized patients with HbE/β-thalassemia when compared with normal subjects [25]. 
In comparison, thrombocytosis, platelet hyperaggregation, and decreased levels 
of protein S, protein C, and antithrombin III were detected in NTDT (such as TI) 
patients (9.4% with splenectomy and 90.6% without splenectomy) [26]. Increased 
oxidative stress of thalassemia platelets was restored by the treatment of iron chela-
tors such as DFO and antioxidants such as NAC and vitamin C [24].
2.2.2.2 Spleen
The spleen is an organ containing some of the RE cells that function to 
destroy RBC hemoglobin by macrophages and store the released iron in 
the form of ferritin and hemosiderin. The number of blood transfusions in 
β-thalassemia major patients seems to correlate with their splenic hemosiderosis 
and splenic weight [27]. Hemosiderin deposition was found to be greater in 
the iron-overloaded livers than in the iron-overloaded spleens. Ferritin and 
hemosiderin increased in hepatocytes and splenic RE cells [28]. Splenectomy is 
one of the therapeutic options in hyper-transfused β-thalassemia major patients 
to reduce hyperactivity of RE macrophages; nevertheless, it may increase the 
iron overload. As a consequence, complications in patients with splenectomized 
thalassemia have included hypercoagulability, an increased incidence of vascular 
thrombosis, and an increased risk of infection. Iron overload in the spleen can 
activate latent nuclear factor-kappa B (NFκB) in alveolar macrophage, reduce 
immunity, and increase susceptibility to infection [29]. Notably, Prx2, which is 
a typical-2 cysteine peroxiredoxin and a key antioxidant system, is upregulated 
during erythropoiesis in patients with β-thalassemia and contributes to the stress 
erythropoiesis in the patients. Nuclear factor erythroid 2 (Nrf2) is a redox-
response transcriptional nuclear factor and cellular adaptive process in response 
to and protection of oxidative stress [30]. Therefore, the regulation of Prx2 and 
Nrf2 genes results in the upregulation of antioxidant (antioxidant responsive 
element, ARE) genes required to ensure the survival of iron-overloaded cells.
2.2.2.3 Liver
The liver is one of the main storage organs for iron. Iron overload is considered 
to be when the ferritin level consistently exceeds 1000 ng/mL (normal range 
20–200 ng/mL). Excess free radicals can cause progressive tissue injury and eventu-
ally cirrhosis or hepatocellular carcinoma in iron overload patients whose iron is 
sequestrated predominantly in ferritin or hemosiderin [31]. When plasma transfer-
rin becomes highly saturated, NTBI is detectable and is rapidly transported across 
the hepatocyte membrane via a specific pathway. Likely, ferroportin 1 is the only 
protein that mediates the transport of iron out of hepatocytes and is then oxidized 
by ceruloplasmin and bound to transferrin. Iron deposition affects hepatic paren-
chymal cells (hepatocytes and bile duct cells) and mesenchymal cells (endothelial 
cells, macrophage, and Kupffer cells) and often distributes differently from one 
area to another [32]. As mentioned above, iron overload can induce ROS which 
can oxidize biomolecules. Lipid peroxidation activates tumor growth factor-beta1 
(TGF-β1) expression which is the most potent pro-fibrogenic cytokine, and its 
expression is increased in almost all of fibrotic diseases. Type I collagen is induced 
by TGFβ resulting in uncontrolled collagen production and leads to tissue scarring 
and organ failure. The scar tissue replaces normal parenchyma, increases fibrosis, 
and blocks the liver portal blood flow consequently generating liver cirrhosis.
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2.2.2.4 Heart
Iron overload cardiomyopathy is a common cause of death in patients with 
β-thalassemia. Biochemically, irons in iron-sulfur clusters and cytochromes are key 
players for oxidative phosphorylation and superoxide production in the mitochon-
dria. Iron deposition in the heart cells seems to lead oxidative stress and cellular 
damage. The heart is the most mitochondrial-rich tissue in the body, making iron of 
particular importance to cardiac function. In cardiac cells, excess iron may result in 
oxidative stress and alteration of myocardial function because of the DNA damage 
caused by hydrogen peroxide through the Fenton reaction. Heart failure is the lead-
ing cause of death among patients with β-thalassemia with hemosiderosis, of whom 
around 60% die from cardiac failure. Harmful effects of iron overload on the heart 
of β-thalassemia major patients can be monitored using noninvasive and invasive 
techniques. Treatment with iron chelators can protect these patients from cardiac 
disease induced by iron overload [33–36].
2.2.2.5 Bone marrow
Bone marrow iron deposition (186 μg/g wet weight) increases in proportion 
to the total body iron stored in a dietary iron overload of African Bantu people 
and Caucasian patients with idiopathic hemochromatosis [37]. Myelodysplastic 
syndrome patients who are a heterogeneous group of clonal hematopoietic stem 
cell malignancies show bone marrow hemosiderosis and also develop systemic iron 
overload.
2.2.2.6 Endocrine glands
Though hematologic care has improved in patients with homozygous trans-
fusion-dependent β-thalassemia, multi-endocrine dysfunction is still a common 
complication. Thyroid dysfunction defined as overt hypothyroidism, subclinical 
hypothyroidism, and exaggerated thyroid-stimulating hormone response was 
reported in patients with β-thalassemia [38]. In addition, lower serum thyroxine 
and higher thyrotrophic hormone levels were found in young patients with thalas-
semia than in normal children. Pituitary siderosis of β-thalassemia major patients 
causes oxidative tissue damage [39], consequently hypogonadotropic hypogonadism 
and growth hormone deficiency. Approximately half of the patients’ pituitary gland 
dysfunction associated with iron overload is irreversible. Toxic irons in patients with 
β-thalassemia major (TDT) and patients with HbE/β-thalassemia are catalytically 
harmful to adrenal glands and can cause adrenal function insufficiency [40]. A 
previous study demonstrated that all β-thalassemia major patients were nondiabetic 
and some of them have decreased oral glucose tolerance test. They showed a normal 
response of cortisol to insulin and adrenocorticotropic hormone stimulation [41]. 
Moreover, the β cell pancreatic function and adrenal cortical function are depressed 
in severe iron loaded. The pancreas is another vital organ for iron accumulation 
especially pancreatic β cell in the islet of Langerhans. Importantly, TDT patients 
present iron deposition in the pancreatic beta cells beginning in the early age of life, 
resulting in decreased insulin secretion [42]. Normal iron level mediates insulin 
secretion via electron transport chain and endoplasmic reticulum calcium release 
by ROS triggering. Inversely, highly accumulated iron produces a high level of ROS 
which damages cell organelles and consequently affects iron-mediated insulin 
secretion mechanism (Figure 1).
As mentioned above, iron overload in thalassemia was assessed with a highly 
elevated level of plasma iron, and highly accumulated tissue iron concentrations 
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lead to many complications. Importantly, effective iron chelators are regularly 
administrated to patients with β-thalassemia for removing the redox iron, amelio-
rating the complications, and prolonging their life expectancy.
2.2.3 Oxidative stress
Iron can participate in the redox process known as the Haber-Weiss/Fenton 
reactions to generate ROS including hydrogen peroxide (H2O2) and hydroxyl radical 
(OH•) (Figure 2) [43]. Subsequently, ROS can oxidize biomolecules such as pro-
teins, carbohydrates, lipids, and nucleic acids in the body causing oxidative tissue 
damage, organ dysfunctions, complications, and pathogenesis [44, 45]. In addition, 
ROS can induce cell apoptosis through initiating serial chemical reactions including 
DNA strand breakage and fragmentation, protein oxidation, and lipids peroxida-
tion [43, 46, 47]. Excessive redox iron can also react with unsaturated lipids to 
produce alkoxyl and peroxyl radicals [48]. These oxidative reactions result in the 
impairment of cellular functions and lead to damage of cells, tissues, and organs, 
which is evident in the iron-loading diseases, β-thalassemia, and Friedreich’s ataxia.
2.3 Assessment methods
For blood samples, the levels of serum iron, TIBC, transferrin saturation, 
ferritin, soluble transferrin receptors, protoporphyrin IX, and routinely measured 
iron parameters indicate whether the body iron status is normal iron balance, iron 
deficiency, or iron overloaded. In addition, the levels of redox irons (e.g., NTBI 
and LPI) and iron-responsive proteins such as EPO, hepcidin, and erythroferrone 
(ERFE) are determined to distinguish the iron imbalance.
Biopsied liver tissue is a clinical sample that is collected for stoichiometric 
determination of nonheme iron. However, this invasive technique requires an 
Figure 1. 
Iron-mediated insulin secretion in pancreatic β cells (modified from [42]). Abbreviations/symbols: 
ATP = adenosine-5′-triphosphate, DMT1 = divalent metal ion transporter 1, Fe2+ = ferrous ion.
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expert hepatologist to operate. The liver tissue will be investigated for its iron 
content using histochemical Pearl’s staining, physical atomic absorption spec-
trometry (AAS), and colorimetric ferrozine methods. Liver iron concentration 
(LIC) is correlated closely with serum ferritin concentration and is a valuable 
alternative to assess visceral iron overload in heavily iron-loaded β-thalassemia 
major patients. In contrast, the collection of other tissues such as the myocar-
dium, liver, pancreas, adrenal glands, anterior pituitary gland, and skin would be 
too harmful to be collected [49]. Sophisticated noninvasive techniques includ-
ing magnetic resonance imaging [50], magnetic iron detector susceptometry, 
superconducting quantum interference device, and nuclear resonance scattering 
are used to assess iron content in tissues. These methods are valuable for evaluat-
ing iron load in the tissues and monitoring the response of different organs to 
chelation therapy.
2.4 Iron chelation therapy
Iron chelation therapy aims to prevent the accumulation of toxic iron and elimi-
nate the excess iron in patients with transfusion-dependent β-thalassemia. Effective 
chelation and good management of the patients have correlated with a decline in 
early deaths and complications. The reduction of plasma and cellular chelatable 
irons (e.g., NTBI, LPI, and LIP) is a slow process and requires aggressive chelation 
therapy. The chelation will maintain the iron balance at safe levels to prevent high 
iron accumulation and oxidative tissue injury. Such non-iron and iron-overloaded 
models as RBC, cell cultures (e.g., hepatocytes, HepG2 cells, and cardiomyocytes), 
animals (e.g. mice, gerbils, rats, and transgenic BKO mice), and even human 
patients with thalassemia are experimentally investigated and clinically tested to 
assess the safety and efficacy of various iron chelators. Individually, DFO, DFP, and 
DFX are promising iron chelators widely used for the treatment of patients with 
β-thalassemia with iron overload. Combined DFO/DFP and DFP/DFX treatments 
can reverse endocrine complications by improving glucose intolerance and gonadal 
dysfunction in TD-TM patients [51].
A combination therapy is when two chelators were combined and presented 
some degree of overlap which pharmacologically lead to improve efficacy and 
rate of iron removal [52–54]. The most extensively studied combination therapy 
is a combination between DFO and the oral chelator DFP which has been shown 
to rapidly reduce liver iron, serum ferritin, and myocardial siderosis compared 
with DFO monotherapy. Clinical trial data for the combination of DFX and DFO 
chelation has reinforced the benefits of combination therapy [55]. In addition, the 
clinical combination of DFX and DFP would be more appealing to patients than 
other combination therapy regimens involving the parenterally administered DFO. 
However, concrete data regarding the safety, efficacy, and dosing of each regimen 
are limited.
Figure 2. 
Iron-catalyzed generation of reactive oxygen species. Abbreviations/symbols: Fe2+ = ferrous ion, Fe3+ = ferric 
ion, SOD = superoxide dismutase.
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In principle, when two chelators are used together, they can act either additively 
or synergistically. Additivity refers to the predicted level of effect achieved by a 
drug combination based on individual drug potencies, whereas synergy refers to 
the exaggerated effect noted upon concurrent use of drugs. Synergism may occur in 
conditions allowing “iron shuttling.” The rate of the chelators’ access to cells, both in 
vitro and in vivo, is determined by size, charge, and lipid solubility of the chelators 
[55–58]. In plasma, the previous demonstration showed that low concentrations of 
DFP can act as a “shuttle” by gaining more rapid access to some non-transferrin-
bound iron (NTBI) pools than DFO and subsequently donating iron to a DFO as a 
“sink” [54]. The isobologram analysis was reported to distinguish between syner-
gistic, additive, or a sub-additive response to iron chelator combinations in human 
hepatic cells (HuH7) [59]. The synergy can imply that the primary chelator can act 
as a “shuttle” for iron chelated and delivered to the secondary “sink” chelator at low 
concentrations (Figure 3).
2.5 Supplementation of antioxidants
All patients with β-thalassemia have higher oxidative stress levels than normal 
people. Hitherto, supplementation of antioxidants has been recommended for them 
to ameliorate oxidative stress, give a better quality of life, and sustain long lives. 
Many antioxidants such as water-soluble vitamins C (L-ascorbic acid), fat-soluble 
vitamin E (α-tocopherol), and vitamin A, β-carotenoids, glutathione, curcumi-
noids, and quercetin are the compounds of interest.
2.5.1 Vitamin C
The levels of AA in leukocytes, platelets, and urine of patients with iron over-
load such as patients with idiopathic hemochromatosis, TDT patient, and Bantu 
people were decreased [60, 61]. After treatment of TM patients with AA, the serum 
levels of iron, transferrin saturation, and ferritin were increased [62]. Possibly, AA 
would involve mobilization of storage iron from tissue ferritin by reducing ferric 
oxyhydroxide to ferrous ion, which will subsequently catalyze ROS production 
via Haber-Weiss reaction and increase oxidative damage in the patients. However, 
Figure 3. 
Iron shuttling mechanism described combination therapy. Abbreviations/symbol: CH = chelator, Fe = iron.
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vitamin C plus vitamin E supplementation seemed to be more effective than vita-
min E alone for promoting antioxidant activity in patients with β-thalassemia [63].
2.5.2 Vitamin E
Evidently, the serum levels of vitamins A, vitamin E, zinc, selenium, and cop-
per were decreased in young patients with thalassemia, while the serum levels of 
retinol and selenium inversely correlated with those of iron and ferritin. Moreover, 
low serum level of vitamin E was found in homozygous β-thalassemia and 
β-thalassemia/Hb E. Administration of vitamin E and polyphenols together with 
iron chelators abolished the increase of oxidative stress in patients with thalassemia, 
suggesting a substantial improvement of their anemia and complications [64]. 
The results from clinical studies using curcuminoids and vitamin E supported the 
free radical scavenging activity in the improvement of oxidative stress and platelet 
functions in patients with thalassemia [65, 66]. Surprisingly, oral administration of 
high doses of vitamin E effectively decreased plasma lipid peroxidation in patients 
with β-thalassemia and prolonged RBC survival in some patients. Furthermore, the 
treatment of TM and TI patients with vitamin E (750 to 1000 IU/day) for 16 months 
showed a fourfold increase in serum and RBC vitamin E levels and a reduction of 
serum malondialdehyde (MDA) level when compared with the untreated group 
[41]. Unchern and colleagues have reported that daily vitamin E supplementation 
for 3 months significantly increased plasma β-tocopherol levels and decreased 
plasma oxidant levels in splenectomized β-thalassemia/Hb E patients [66].
2.5.3 N-Acetylcysteine
NAC is a potent antioxidant and free radical scavenger, which involves glutathi-
one biosynthesis and promotes detoxification. It is utilized for the treatment option 
for sickle cell anemia and diseases involved in the generation of ROS. Under iron 
overload condition, NAC provides a protective effect on brain dysfunction in iron-
overloaded rats; therefore, the compound can diminish ROS production and DNA 
damage in patients with β-thalassemia [67–69].
2.5.4 Natural products
Quercetin is one of the predominant flavonoids of polyphenolics found in many 
fruits, vegetables, leaves, grains, red onions, kale, apples, and tea. Flavonoids are 
commonly present in their glycosylated form in the diet and presence of aglycone, 
glycoside, as well as methyl, glucuronide, and sulfate conjugates, which have been 
reported in human plasma. Quercetin has been reported to exert antioxidant and 
free radical scavenging properties in vitro, while quercetin supplementation has 
been promoted for the treatment of cancer and other diseases. Surprisingly, dietary 
quercetin supplementation was found to attenuate liver injury in iron-overloaded 
mice [70]. As a novel idea, we wish to investigate their role as adjuncts in iron 
mobilization [71].
Curcuminoids are the phytochemicals from turmeric Curcuma longa Linn (family 
Zingiberaceae), which are composed of three main constituents including cur-
cumin, demethoxycurcumin, and bis-demethoxycurcumin, in which the important 
bioactive molecular structure is diketone moiety. Curcumin was found to suppress 
the ROS generation and lipid peroxidation in erythrocytes. Surprisingly, curcumin 
metabolites including di-, tetra-, and hexa-hydrocurcumin exhibit strong antioxi-
dant, free radical scavenging, anti-lipid peroxidative and iron-chelating properties. 
The other effects are antithrombotic and anti-inflammatory activities. Oxidative 
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stress condition in red blood cells of β-thalassemia/HbE patients is reduced after 
treatment with curcuminoids [65], leading to an improvement of their quality 
of life.
Green tea exhibits many interesting biological, biochemical, and pharmacologi-
cal properties in health benefits. Normally, tea leaves (Camellia sinensis) are pro-
cessed without fermentation for the preparation of green tea extract (GTE), which 
is abundant with epigallocatechin-3-gallate (EGCG) and exhibits antioxidative 
iron-chelating activity. In a recent study, the effect of GTE products on the status 
of iron overload, oxidative stress, and endocrine hormones was studied in iron 
overload pancreatic and liver cell lines, β-thalassemic mice, and β-thalassemia/HbE 
patients.
3. Green tea for thalassemia’s health
Green tea is prepared without fermentation from tea leaves and one of the 
most popular beverages in the world. It is composed of proteins, amino acids 
(e.g., 5-methylglutamine, glutamic acid, tryptophan, glycine, serine, aspartic 
acid, tyrosine, valine, leucine, threonine, arginine, and lysine), carbohydrates 
(e.g., cellulose, pectin, glucose, fructose, and sucrose), lipids (e.g., linoleic acid 
and α-linolenic acids), sterols (e.g., stigmasterol), vitamin B, vitamin C, vitamin 
E, caffeine, theophylline, chlorophyll, carotenoids, volatile compounds (e.g., 
aldehydes, alcohols, esters, lactones, and short-chain hydrocarbons), minerals, 
and essential elements. Importantly, green tea is rich in polyphenols, particularly 
flavonoids (0.5–1.5%) in forms of catechins (flavan-3-ols). Five main green tea 
catechins (GTC) are included, EGCG which is the main proportion (59% of total 
catechins), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG), and 
(−)-epicatechin (EC) (Figure 4). In addition, green tea contains gallic acid, 
chlorogenic acid, caffeic acid, kaempferol, myricetin, and quercetin. During the 
fermentation process, flavonoids in green tea are oxidized into theaflavins and 
thearubigins, which are the main ingredients in black tea.
In health benefits, green tea plays many important roles in cells and systems 
in the body. Green tea has been considered a medicine and a healthful beverage 
since ancient times. Traditional Chinese medicine has recommended this plant 
for headaches, body aches and pains, digestion, depression, detoxification, as an 
energizer, and, in general, to prolong life. Caffeine acts mainly upon the central 
nervous system, stimulating wakefulness, facilitating ideas association, and 
decreasing the sensation of fatigue [73]. Green tea polyphenols present antioxi-
dant, ROS and reactive nitrogen species (RNS) scavenging, and metal-chelating 
activities [72, 74, 75]. They may also function indirectly through (1) inhibition 
of redox-sensitive transcription factors; (2) inhibition of “prooxidant” enzymes 
including inducible nitric oxide synthase (iNOS), lipoxygenase (LOX), cyclo-
oxygenase (COX), and xanthine oxidase (XO); and (3) induction of antioxidant 
enzymes including GST and SOD [76].
3.1 Neuronal cells
We have presented that GTE treatment at 0–100 μg/mL was not toxic to the 
neuroblastoma (SH SY5Y) cells (viability >90%). Nevertheless, the cell viability 
significantly decreased in iron-loaded condition, and the treatment of the cells 
with GTE (10–40 μg/mL) was found to improve the viability. GTE monotherapy 
(10–20 μM) was not effective to reduce LIP levels in SH SY5S cells, whereas com-
bined treatment with GTE and CM1 iron chelator significantly reduced the LIP. 
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Moreover, GTE monotherapy (40 μM), as well as the combination of GTE and CM1 
chelator, exhibited significant free radical scavenging activity in a concentration-
dependent manner [77]. Consistently, Xu and colleagues have reported that the oral 
administration of EGCG (25 mg/kg/day, 7 days) regulated the iron-export protein 
ferroportin in the substantia nigra and reduced oxidative stress in Parkinson’s 
disease mice [78].
3.2 Blood cells
Phenolic acids (e.g., chlorogenic acid, caffeic acid, and gallic acid) and flavonols 
(e.g., kaempferol, myricetin, and quercetin) are present in green tea. GTE and 
EGCG, which show iron-chelating and antioxidant properties, decrease labile 
iron (e.g., NTBI and LPI) levels and consequently deplete lipid peroxidation as 
well as oxidative stress in both iron-loaded rats and thalassemic mice [73, 74]. The 
compounds were effective in the inhibition of RBC hemolysis, resulting in pro-
longed RBC lifespan and decreased iron deposition and oxidative damage in liver 
[75]. Logically, antioxidative GTE interferes duodenal absorption of dietary iron 
and iron-chelating properties in vitro and in vivo. The preparation also shows the 
inhibitory effect on catecholamine secretion from isolated rabbit adrenal glands, 
possibly by blocking LTCC in the adrenomedullary glands. Active compounds in 
GTE are effective in the inhibition of red blood cell hemolysis; therefore, red blood 
cell lifespan can be expanded, and iron deposition in the liver can be decreased [79]. 
Green tea extract improves the abnormality of sickle red cells [80]. Using fluoro-
chrome labeling and flow cytometry, we found feeding ferrocene diet-induced 
iron overload and oxidative stress, leading to a significant decrease of RBC survival 
half-time (T1/2) in WT (T1/2 = 23 days) and BKO thalassemic mice (T1/2 = 13 days) 
when compared with feeding normal diet (T1/2 = 30 days). Surprisingly, the RBC 
survival rate was approximately 15% increase in GTE-treated WT mice and 27% 
increase in GTE-treated BKO mice when compared with placebo-treated WT mice 
(Ounjaijean, S. unpublished data). Antioxidative GTE, particularly EGCG, would 
possibly scavenge ROS and recycle oxidized glutathione (GSSG) to GSH in RBC 
cytoplasm, leading to the inhibition of RBC hemolysis and prolonged RBC survival. 
Tea extracts can be used as a therapeutic agent in case of anemia resulting from 
red blood cell destruction and alleviate infection-induced inflammation or other 
Figure 4. 
Chemical structures of five catechins in green tea (modified from [72]). Abbreviations: C = catechin, 
EC = epicatechin, ECG = epicatechin-3-gallate, EGC = epigallocatechin, EGCG = epigallocatechin-3-gallate.
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inflammatory diseases [81, 82]. EGCG is presented to ameliorate inflammation via 
the nuclear factor erythroid-derived 2-like-2 (Nrf2 signaling pathway), leading to 
prevent osteoblasts [83]. On the other hand, excessive green tea consumption may 
cause iron-deficiency anemia [67].
3.3 Liver and pancreas cells
By using lactate dehydrogenase assay, Koonyosying and colleagues have found 
that GTE at 1–10 μM EGCG equivalent was not toxic to rat insulinoma (RINm-5F) 
cells, whereas GTE doses of 1–30 μM EGCG equivalent were not toxic to human 
hepatocellular carcinoma (Huh7) cells either, showing 20% inhibitory concentra-
tions (IC20) of 10.6 and 17.4 μM EGCG equivalent, respectively [84]. Interestingly, 
GTE monotherapy (10 μM EGCG equivalent) revealed an almost twofold reduction 
of LIP in iron-loaded RINm-5F and Huh7 cells when compared to treatment without 
GTE, while GTE treatment (1 and 10 μM EGCG equivalent) together with 10 μM 
DFO showed a synergistic effect of the LIP mobilization. Similarly, the GTE treat-
ments efficiently lowered ROS levels in these two cells in the same manner. Most 
importantly, the GTE treatments effectively restored the production of insulin from 
iron-loaded RINm-5F cells and hepcidin production from iron-loaded Huh7 cells, 
indicating relief of endocrine gland dysfunction from iron-induced oxidative tissue 
damage [84].
3.4 Hypercoagulability and thrombosis in thalassemia
Oral green tea catechins significantly inhibited arachidonic acid (AA)-induced 
platelet aggregation in rats [85]. Likewise, EGCG suppressed adenosine diphosphate 
(ADP)-induced platelet aggregation in a dose-dependent manner and reduced the 
ADP-induced phosphorylation of p38 mitogen-activated protein kinase and heat 
shock protein [86]. In addition, EGCG inhibited the ADP-stimulated release of 
platelet-derived growth factor-AB and soluble CD40 ligand [87]. Moreover, green 
tea catechins inhibited ATP release from dense granules in washed platelets and AA 
liberation stimulated by collagen in platelets [85]. Interestingly, GTC and EGCG 
prevented death due to pulmonary thrombosis, prolonged bleeding time in mice in 
vivo, and inhibited human platelet aggregation [88]. Nowadays, the life expectancy 
of TM patients has been improved because of regular blood transfusions and iron 
chelation therapy. However, patients with thalassemia still suffer from many compli-
cations from their chronic disease. Regular transfusion therapy leads to iron overload-
related complications including growth retardation, hypoparathyroidism, diabetes 
and impaired glucose intolerance, osteoporosis, cardiomyopathy, liver fibrosis, and 
cirrhosis [89]. Heart failure and arrhythmia have been reported as the main cause of 
death in TM patients, whereas pulmonary hypertension and thrombosis are also the 
major cardiovascular complications in TI patients possibly due to pro-atherogenic 
biochemical factors (e.g., iron status and lipid profile) [90–94]. Hypercoagulable pul-
monary microthromboembolism in Thai pediatric TE patients was previously inves-
tigated [95]. TI patients had thrombosis (9.4%), thrombocytosis (15%), mostly after 
splenectomy, and lower levels of anticoagulation inhibitors (e.g., protein S, protein C, 
and antithrombin III) (15%) [26]. Splenectomy also promotes portal vein thrombosis 
in TM patients [96]. Ineffective erythropoiesis, chronic anemia, iron overload, and 
polycythemia by erythrocytosis and thrombosis are coincidently occurring in patients 
with 𝛽-thalassemia. Signs of cerebrovascular accident (brain ischemia, hemorrhage, 
and infarct) and heart disease (congestive heart failure and atrial fibrillation) were 
described in patients with chronically hypercoagulable thromboembolic thalassemia, 
so anticoagulant and/or anti-platelet therapy is recommended [97].
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According to a high incidence of coagulopathy affecting life expectancy, patients 
with thalassemia have been reported recently to understand contributing factors. 
Thrombosis related to the hypercoagulable state in thalassemia has been mostly 
reported. Factors contributing to the hypercoagulable state in patients have been 
identified [98]. Hypoxia and iron overload are the two major mechanisms of ROS 
overproduction that can cause oxidative tissue damage and complications [99]. The 
levels of plasma hemostatic and thrombotic markers including thrombin-antithrom-
bin III complex, β2 thromboglobulin, C-reactive protein, tissue plasminogen activator 
antigen, protein C, protein S, antithrombin, prothrombin fragments, fibrinogen, 
and lipoprotein (a) were significantly higher in patients with splenectomized 
HbE/β-thalassemia than non-splenectomized ones, implying that splenectomy 
increases platelet hyperactivity, blood hypercoagulability, and risk of thrombosis 
[100, 101]. ROS-induced activation of vascular endothelial cells can cause vasculitis 
and thrombosis, showing increased levels of soluble adhesion molecules such as 
intercellular adhesion molecule-1 (ICAM-1), E-selectin (ELAM-1), vascular cell 
adhesion molecule-1 (VCAM-1), and von Willebrand factor (vWF) in thalassemia 
blood [102]. Procoagulant activity of circulating damaged RBC or RBC microvesicles 
may also contribute to thrombotic events in thalassemia hypercoagulability [103]. 
Carotid artery thrombus is usually associated with severe cardiovascular diseases 
(CVD), iron-deficiency anemia, and thrombocytosis. Thromboembolic complica-
tions are documented in patients with thalassemia, possibly due to the aggregability 
of abnormal RBC and high amounts of RBC membrane-derived microparticles [104]. 
The treatment of β-thalassemia/HbE patients with antioxidants can improve oxidative 
stress and hypercoagulable state [105]. Particularly, NTBI presenting in thalassemia 
plasma would be one of the risk factors in pulmonary thrombosis and hypertension in 
splenectomized NTDT patients [106]. DFO and DFP were effective in the ameliora-
tion of iron overload and oxidative stress in thalassemic mice, possibly in the preven-
tion of pulmonary thrombosis [107].
Excessive iron and carbon monoxide liberated from heme oxygenase-1 catalyzed 
heme degradation also contribute to hypercoagulability [108]. Moreover, low argi-
nine bioavailability and elevated arginase I activity in patients with β-thalassemia 
are possible causes of pulmonary hypertension leading to cardiopulmonary 
dysfunctions [109]. However, there are no difference in serum arginine between 
young patients with β-thalassemia and young control children [110]. Anemia (e.g., 
iron-deficiency anemia) can be linked to cerebral venous thrombosis as well [111]. 
Ex vivo Hb released from old RBC and in vivo Hb released from thalassemia RBC 
per se directly bind nitric oxide, whereas arginase will degrade available arginine 
during hemolysis [112]. Splenectomy, thrombocytosis, and only platelet MP are 
proposed to be residual hypercoagulable/thrombotic risks in TDT patients [23, 113]. 
Liver diseases such as liver inflammation and cirrhosis can involve in hypercoagula-
bility, thrombosis, and reduced fibrinolysis [114, 115].
3.5 β-Thalassemic mice
Upanan and colleagues have demonstrated that hepatic hepcidin gene (Hamp1) 
mRNA levels in heterozygous β-globin knockout thalassemic mice (BKO, muβth-
3/+) were significantly lower than that in wild-type mice (WT, muβ+/+) and 
significantly upregulated with iron loading. However, combined treatment of DFP 
(50 mg/kg) and GTE (50 mg EGCG equivalent) for 90 days was more effective in 
the upregulation of the Hamp1 mRNA levels in BKO thalassemic mice significantly. 
Similarly, monotherapy with the GTE effectively decreased serum levels of alanine 
aminotransferase in BKO thalassemic mice (∆11 + 9 U/L), while the combined 
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GTE/DFP chelation showed greater effect (∆1 + 9 U/L) (P < 0.05) when compared 
without GTE (∆17 + 12 U/L), suggesting protection of oxidative liver damage. 
Likewise, GTE monotherapy and GTE plus DFP therapy was found to lower the 
levels of serum NTBI, spleen, and liver iron from iron-loaded BKO mice significantly 
when compared without GTE treatment [84, 116]. Currently, Al-Basher has shown 
that oral administration of GTE (100 mg/kg) for two more months lowered iron 
Figure 5. 
Challenging with green tea for treatments of iron overload and oxidative: from cells to bedsides. Abbreviations/
symbols: BKO = β-globin knockout, BUN = blood urea nitrogen, EGCG = epigallocatechin-3-gallate, 
GTE = green tea extract, HepG2 cells = human hepatocellular carcinoma cells, HPLC = high-performance 
liquid chromatography, Huh7 cells = human hepatocellular carcinoma cells, RBC = red blood cells, RINm5F 
cells = rat insulinoma cells, ROS = reactive oxygen species, SH SYS9 = human neuroblastoma cells, red 
alphabet = iron overload.
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accumulation, improved antioxidant capacity, and restored the increase of hepcidin 
in the livers of iron-overloaded rats [117]. Recently, Koonyosying and colleagues have 
demonstrated that GTE decreased the amounts of iron in the livers (P < 0.05) and 
pancreas insignificantly from iron-loaded BKO mice; however, combination therapy 
of DFP and GTE was not efficient superior to the GTE monotherapy in the two cells 
[84]. Similarly, GTE treatment efficiently lowered the levels of lipid peroxidation 
products such as plasma TBARS and tissue MDA in liver and pancreatic tissues from 
BKO mice fed with ferrocene diet, and the combined treatment was not superior to 
the GTE monotherapy either [84]. Consistent with studies of the cells, GTE restored 
the production of hepatic hepcidin and pancreatic insulin in iron-loaded BKO mice, 
and the combined treatment was not more efficient over the GTE monotherapy [84]. 
The findings suggest protective effects of iron-induced oxidative hepatic and pan-
creatic damages by GTE, which the action would be mainly free radical scavenging 
property.
3.6 Patients with β-thalassemia
A recent study of controlled trial in British healthy volunteers has demon-
strated that the interval between meal consumption and tea consumption did not 
affect plasma levels of hepcidin-25 [118]. Surprisingly, the consumption of GTE-
curcumin drinks for 60 days tentatively decreased the levels of Hb, Hct, and RBC 
numbers in TDT patients [84]. Moreover, the drink with the GTE dose of 50 mg 
EGCG equivalent was found to lower the levels of NTBI and LPI. Taken together, 
green tea polyphenols and curcuminoids present in the drink could possibly 
interfere absorption of dietary iron and mobilize delivery of iron to the erythrons 
[65, 79, 119]. Taken all our studies, we summarize the applications of nutraceuti-
cal green tea extract for the amelioration of iron-overloaded cells, β-thalassemic 
mice, and patients with β-thalassemia (Figure 5) [79, 84, 106, 116, 119–128]. In our 
expectations, we hope the patients will have safer chelation therapy, a better quality 
of lives, and good health.
4. Conclusions
Patients with β-thalassemia suffer from ineffective erythropoiesis and chronic 
anemia and from secondary iron overload caused by multiple blood transfusions 
and increased iron absorption. Iron chelation therapy and antioxidant administra-
tion are supportive treatments to ameliorate iron overload and oxidative tissue 
damage. Green tea (Camellia sinensis) abundant with EGCG possesses diuretic, free 
radical scavenging, and iron-chelating properties. Accordingly, green tea products 
can decrease the levels of redox-active iron, ROS, and lipid peroxidation products 
in iron-overloaded cells, β-thalassemic mice, and patients. In addition, green tea 
can restore pancreatic insulin secretion and hepatic hepcidin production from 
hepatocytes with iron overload. Furthermore, the nutraceutical properties of green 
tea products have to be investigated intensively in patients with oxidative stress and 
neurodegenerative disorders.
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AA arachidonic acid
ADP adenosine 5′-phosphate
AE2 anion-exchange protein 2
ARE antioxidant responsive element
ATP adenosine-5′-triphosphate
BKO beta-globin knockout
BUN blood urea nitrogen
CAT catalase
CH chelator
COX cyclooxygenase
DFO desferrioxamine
DFP deferiprone
DFX deferasirox
DMT1 divalent metal ion transporter 1
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ECG epicatechin-3-gallate
EGC epigallocatechin
EGCG epigallocatechin-3-gallate
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Fe iron
Fe2+ ferrous ion
Fe3+ ferric ion
GI gastrointestinal
GPx glutathione peroxidase
GR glutathione reductase
GSH reduced glutathione
GSSG oxidized glutathione
GST glutathione-S-transferase
GTC green tea catechins
GTE green tea extract
Hamp1 hepatic hepcidin gene
Hb hemoglobin
HbA hemoglobin A
HbA2 hemoglobin A2
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Hct hematocrit
HbE hemoglobin E
HbF fetal hemoglobin
HbH hemoglobin H
HepG2 human hepatocellular carcinoma cells
H2O2 hydrogen peroxide
HPLC high-performance liquid chromatography
Huh7 human hepatocellular carcinoma cells
IC20 20% inhibitory concentrations
iNOS inducible nitric oxide synthase
IRE iron regulatory element
IRP iron regulatory protein
LIC liver iron concentration
LIP labile iron pools
LOX lipoxygenase
LPI labile iron pool
LTCC L-type calcium channel
MDA malondialdehyde
MP microparticles
NAC N-acetylcysteine
NFκB nuclear factor-kappa B
Nrf2 nuclear factor erythroid 2
NTBI non-transferrin-bound iron
Nramp2 natural resistance-associated macrophage protein 2
NTDT non-transfusion-dependent β-thalassemia
OH• hydroxyl radical
Prx2 peroxiredoxin 2
RBC red blood cells
RE reticuloendothelial
RINm5F rat insulinoma cells
RNS reactive nitrogen species
ROS reactive oxygen species
SH SY5Y neuroblastoma cells
SOD superoxide dismutase
T1/2 half-time
TBARS thiobarbituric acid-reactive substances
TBI transferrin-bound iron
TDT transfusion-dependent β-thalassemia
Tf transferrin
TfR1 transferrin receptor 1
TGF-β1 tumor growth factor-beta1
TI β-thalassemia intermedia
TIBC transferrin iron-binding capacity
TM β-thalassemia major
TTCC T-type calcium channel
TTCC T-type calcium channel
XO xanthine oxidase
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